XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants

• Published in: bioRxiv
• Main Authors: Jain, Shilpi, Kumar, Sanjeev, Lai, Lilin, Linderman, Susanne, Malik, Ansa A, Ellis, Madison L, Godbole, Sucheta, Solis, Daniel, Sahoo, Malaya K, Bechnak, Kareem, Paredes, Isabel, Tanios, Ralph, Kazzi, Bahaa, Dib, Serena M, Litvack, Matthew B, Wimalasena, Sonia T, Ciric, Caroline, Rostad, Christina, West, Richard, Teng, I-Ting, Wang, Danyi, Edupuganti, Sri, Kwong, Peter D, Rouphael, Nadine, Pinsky, Benjamin A, Douek, Daniel C, Wrammert, Jens, Moreno, Alberto, Suthar, Mehul S
• Format: Journal Article Paper
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 05.02.2024; Cold Spring Harbor Laboratory
• Edition: 1.1
• Subjects: Clinical trials; COVID-19; Immunoglobulin G; Immunological memory; Immunology; Lymphocytes B; Memory cells; mRNA; Severe acute respiratory syndrome coronavirus 2; Vaccines

The rapid emergence of divergent SARS-CoV-2 variants has led to an update of the COVID-19 booster vaccine to a monovalent version containing the XBB.1.5 spike. To determine the neutralization breadth following booster immunization, we collected blood samples from 24 individuals pre- and post-XBB.1.5...